Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer medicine"
DOI: 10.1002/cam4.4681
Abstract: BACKGROUND Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active… read more here.
Keywords: study; nivolumab cabozantinib; progression nivolumab; cabozantinib ... See more keywords